10 March 2017
: Case report
Late-Onset Cerebral Toxoplasmosis After Allogeneic Hematopoietic Stem Cell Transplantation
Unusual clinical course, Challenging differential diagnosis, Unusual or unexpected effect of treatment, Diagnostic / therapeutic accidents, Educational Purpose (only if useful for a systematic review or synthesis)
Ahmed M. Khalaf1ABDEF*, Mahmoud A. Hashim23ABDEF, Mohammed Alsharabati4BD, Kenneth Fallon5BD, Joel K. Cure6BD, Peter Pappas7BD, Shin Mineishi8D, Ayman Saad9ABDEGDOI: 10.12659/AJCR.899687
Am J Case Rep 2017; 18:246-250
Abstract
BACKGROUND: Toxoplasmosis is an uncommon but potentially fatal complication following allogeneic hematopoietic stem cell transplantation (HCT). Post-transplant toxoplasmosis is often a reactivation of prior infection and typically occurs within the first 6 months of transplant. Herein, we report that cerebral toxoplasmosis may occur 22 months after allogeneic hematopoietic stem cell transplantation.
CASE REPORT: We describe a case of cerebral toxoplasmosis that occurred 22 months after an allogeneic HCT while the patient was on aerosolized pentamidine for Pneumocystis jiroveci pneumonia (PCP) prophylaxis. The disease was only diagnosed after brain biopsy because of atypical MRI appearance of the cerebral lesion and negative Toxoplasma gondii IgG antibody test result in the cerebrospinal fluid (CSF). The patient received pyrimethamine and sulfadiazine treatment, with dramatic improvement after several months. The patient is alive 2 years after infection diagnosis, with no evidence of disease and is off Toxoplasma prophylaxis.
CONCLUSIONS: Cerebral toxoplasmosis can occur late after allogeneic HCT while patients are on immunosuppression therapy, with atypical features on imaging studies and negative Toxoplasma gondii IgG antibody test result in the CSF. Pre-transplant serologic screening for T. gondii antibodies in allogeneic transplant candidates is warranted. Brain biopsy can be a helpful diagnostic tool for cerebral lesions.
Keywords: Toxoplasmosis, Toxoplasmosis, Cerebral, case reports, Brain Biopsy, Late Reactivation, prophylaxis, Toxoplasma gondii
SARS-CoV-2/COVID-19
29 March 2023 : Editorial
Med Sci Monit In Press; DOI: 10.12659/MSM.940519
21 March 2023 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.938730
21 March 2023 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.938659
22 February 2023 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.938732
In Press
30 Mar 2023 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.939200
30 Mar 2023 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.939365
28 Mar 2023 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.939387
27 Mar 2023 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.939170
Most Viewed Current Articles
06 Dec 2021 : Case report
DOI :10.12659/AJCR.934406
Am J Case Rep 2021; 22:e934406
13 Jul 2022 : Case report
DOI :10.12659/AJCR.936441
Am J Case Rep 2022; 23:e936441
23 Feb 2022 : Case report
DOI :10.12659/AJCR.935250
Am J Case Rep 2022; 23:e935250
07 Dec 2021 : Case report
DOI :10.12659/AJCR.934347
Am J Case Rep 2021; 22:e934347